You are logged on as Guest.
RegisterLoginShopping cart (Empty)
 United States

Toll-like receptor 3 (human), mAb (TLR3.7)

 
ALX-804-474-C050 50 µg 220.00 USD
 

Product Specification

Alternative Name:TLR3, CD283
 
Concentration:0.2mg/ml.
 
Formulation:Liquid. Purified antibody in PBS containing 10% glycerol. Does not contain any preservatives.
 
Clone:TLR3.7
 
Isotype:Mouse IgG1
 
Immunogen:Recombinant human TLR3 (Toll-like receptor 3).
 
Specificity:Recognizes human TLR3.
 
Application:Flow Cytometry
Immunocytochemistry
Immunoprecipitation
Functional Application (blocks double-stranded RNA-mediated signalling)
 
Long Term Storage:-20°C
 
Use/Stability:Stable for at least 1 year after receipt when stored as recommended.
 
Handling:Avoid freeze/thaw cycles.
 
804-474 FUNC
Figure: Clone TLR3.7 inhibits dsRNA-induced IFN-b production by MRC-5 cells.
804-474 IP
Figure: Immunoprecipitation of human TLR3 in transfectants with clone TLR3.7.
804-474 FC
Figure: FC with clone TLR3.7.
Please mouse over
804-474 FUNC 804-474 IP 804-474 FC

Product Literature References

Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains: M. Tanabe, et al.; BBRC 311, 39 (2003), Abstract;
Subcellular localization of Toll-like receptor 3 in human dendritic cells: M. Matsumoto, et al.; J. Immunol. 171, 3154 (2003), Abstract;
Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling: M. Matsumoto, et al.; BBRC 293, 1364 (2002), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet 

RELATED PRODUCTS

By catalog section:
By biological activity:
TLR Monoclonal antibody

PRODUCT SUPPORT

Technical Service
Bulk Quantity Quote
Customer Service

Related Literature

Product Flyers
Key TLR Ligands and their Receptors
Add to order list
Key TLR Ligands and their Receptors 21-Oct-09
Download as PDF

Antiviral Signaling
Add to order list
Antiviral Signaling 17-May-09
Download as PDF

All new literature pieces

©2010 Enzo Life Sciences, Inc.,